Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|November 25, 2010
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trialsLuisa Bonilla, Irit Ben-Aharon, Liat Vidal, et al.
Plos One|September 21, 2011
In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vesselsHadas Bar-Joseph, Irit Ben-Aharon, Moran Tzabari, et al.
Anti-Cancer Drugs|January 14, 2012
The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experienceIrit Ben Aharon, Ofer Purim, Yulia Kundel, et al.
Cancer Reports (Hoboken, N.J.)|August 5, 2021
Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancerOran Zlotnik, Tal Goshen-Lago, Riad Haddad, et al.
Frontiers in Oncology|March 19, 2020
miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer LinesLihi Ninio-Many, Elad Hikri, Tamar Burg-Golani, et al.
Cancer Discovery|February 9, 2023
Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and ImplicationsIrit Ben-Aharon, Hanneke W M van Laarhoven, Elisa Fontana, et al.
Plos One|August 31, 2013
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisIrit Ben-Aharon, Liat Vidal, Shulamith Rizel, et al.
Biomedicines|December 10, 2020
Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity-From Bench to BedsideMattan Levi, Tal Goshen-Lago, Rinat Yerushalmi, et al.
Reproductive Biology and Endocrinology : RB&E|March 6, 2010
Doxorubicin-induced ovarian toxicityIrit Ben-Aharon, Hadas Bar-Joseph, Galia Tzarfaty, et al.
American Journal of Clinical Oncology|November 22, 2022
Predicting Factors for a Favorable Pathologic Response to Neoadjuvant Therapy in Esophageal CancerOry Wiesel, Oran Zlotnik, Sarah Morgenstern, et al.
Pageof 10